Ikena is a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer.
Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.
Our programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging our deep understanding of discovery chemistry, translational science, and patient-centric drug development, we have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables us to target specific patient populations that we believe are most likely to respond to treatment with our product candidates. We have assembled an experienced and well-respected team of drug hunters, translational researchers, clinicians and entrepreneurs drawn from many of the largest innovators in biotechnology, supported by top-tier investors and partners, as well as world-class advisors, to advance and broaden our portfolio of novel, patient-directed oncology therapies.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $160M
Founded date: 2016
Investors 4
| Date | Name | Website |
| 21.02.2021 | Logos Capi... | logoscapit... |
| - | Omega Fund... | omegafunds... |
| - | OrbiMed | orbimed.co... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.05.2023 | - | $40M | - |
| 05.01.2021 | Series B | $120M | Omega Fund... |
Mentions in press and media 10
| Date | Title | Description |
| 15.12.2025 | DISCO Pharmaceuticals: €36 Million Seed Funding Raised And Mark Manfredi Named As CEO | DISCO Pharmaceuticals has appointed biotech executive Mark Manfredi, Ph.D., as chief executive officer and completed the final close of a €36 million seed financing round to advance its pipeline of surfaceome-targeted drug candidates for ha... |
| 12.03.2024 | Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results | - |
| 15.05.2023 | Ikena Oncology Announces $40 Million Underwritten Offering | - |
| 15.05.2023 | Ikena Oncology Announces $40 Million Underwritten Offering | - |
| 17.03.2022 | Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update | Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024 Advanced IK-930, lead targeted oncology program, into the clinic, continuing leadership in the Hippo pathway therapeutic landscape Expanded... |
| 10.11.2021 | Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update | IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022 Progressing RAS pathway research programs with multiple development candidates expected in the next 18 months Investigator-initiated trial launched ev... |
| 05.11.2021 | Ikena Oncology Corporate Presentation - November 2021 | 1 Disclaimer This Presentation contains forward-looking statements and information. All statements other than statements of historical facts contained in this Presentation, including statements regarding our strategy, future financial condi... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc., a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | Ikena Oncology, Inc. (“Ikena”), a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven cancer therapies, today announces the closing of $120 million in an oversubscribed Series B financing. The... |
| 05.01.2021 | Ikena Oncology Closes $120 Million Series B Financing Led by Omega Funds | - |